Cover Image
市場調查報告書

尼古丁中毒症:開發中產品分析

Nicotine Addiction - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245978
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
尼古丁中毒症:開發中產品分析 Nicotine Addiction - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 57 Pages
簡介

尼古丁中毒是由於尼古丁藥物成癮所引起的香煙產品成癮症。致病要素有年齡、憂鬱症傾向、思覺失調症、PTSD、酒精成癮等,停止攝取尼古丁時會出現手顫抖、發汗、神經過敏、心律上升等禁斷症狀。可用尼古丁替代療法進行治療。

本報告提供尼古丁中毒症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

尼古丁中毒症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

尼古丁中毒症:企業開發中的治療藥

尼古丁中毒症:大學/機關研究中的治療藥

尼古丁中毒症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

尼古丁中毒症:企業開發中的產品

尼古丁中毒症:大學/機關研究中的產品

尼古丁中毒症的治療藥開發企業

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

尼古丁中毒症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

尼古丁中毒症:最近的開發平台趨勢

尼古丁中毒症:暫停中的計劃

尼古丁中毒症:中止開發的產品

尼古丁中毒症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9063IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape.

Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post-traumatic stress disorder and alcoholism. Person experiences withdrawal symptoms at cessation of using, such as shaky hands, sweating, irritability, or rapid heart rate. Treatment includes nicotine replacement therapy (NRT).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nicotine Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nicotine Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Nicotine Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nicotine Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Nicotine Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nicotine Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nicotine Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nicotine Addiction (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nicotine Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nicotine Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nicotine Addiction - Overview
  • Nicotine Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Nicotine Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nicotine Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Astraea Therapeutics LLC
    • C4X Discovery Holdings PLC
    • Chronos Therapeutics Ltd
    • CV Sciences Inc
    • Hager Biosciences LLC
    • Heptares Therapeutics Ltd
    • Omeros Corp
    • Savant HWP Inc
  • Nicotine Addiction - Drug Profiles
    • (cannabidiol + nicotine bitartrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EORA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nicotine Addiction - Dormant Projects
  • Nicotine Addiction - Discontinued Products
  • Nicotine Addiction - Product Development Milestones
    • Featured News & Press Releases
      • May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development
      • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
      • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
      • Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
      • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nicotine Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by Astraea Therapeutics LLC, H1 2017
  • Nicotine Addiction - Pipeline by C4X Discovery Holdings PLC, H1 2017
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by CV Sciences Inc, H1 2017
  • Nicotine Addiction - Pipeline by Hager Biosciences LLC, H1 2017
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Nicotine Addiction - Pipeline by Omeros Corp, H1 2017
  • Nicotine Addiction - Pipeline by Savant HWP Inc, H1 2017
  • Nicotine Addiction - Dormant Projects, H1 2017
  • Nicotine Addiction - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Nicotine Addiction, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top